“At HHC, the nation's largest municipal health care system, savings from the program have enabled us to serve millions of low income and vulnerable New Yorkers and to re-invest savings in innovative programs focused on reducing readmission and improving our patients' outcomes.” – New York City Health and Hospitals Corporation
“For 20 years, the 340B Drug Pricing Program has helped vulnerable patients get the medications they need, regardless of their ability to pay. In New York, savings generated by the 340B program has been reinvested in innovative programs to ensure low-income patients obtain the medications they need and avoid unnecessary hospitalizations-programs that would be unsustainable without this valuable program.” – New York Community Hospital
“Frankly, every dollar of additional cost caused by increased pharmaceutical prices, or by additional administrative overhead required to comply with new regulations, threatens our ability to serve our low-income and uninsured patients.” – Ellis Hospital
“In keeping with the spirit of 340B ECMC provides substantial assistance to patients in the form of free medications through an indigent drug program. This service promotes earlier discharge from the hospital and ensures a safe transition home or to community partners. The scope of this program is vastly expanded thanks to the savings from 340B, with annual expenditures frequently in excess of $250,000.” – Erie County Medical Center
“The 340B Drug Pricing program is an essential tool for safety net hospitals that are constantly challenged to develop sustainable financial strategies that support the provision of health care to the underserved. The program allows certain facilities, including the Mount Sinai Health System, that serve a disproportionate share of low-income, uninsured, and underinsured patients, to purchase outpatient drugs at a significantly discounted price. Those drug savings can then be redirected to promote programs that assist the Hospital's underserved communities.” – Mount Sinai Health System
***NOTE: The above information is derived from public comments filed on regulations.gov in response to HRSA’s proposed mega-guidance. Use here does not imply any affiliation with 340B Matters or endorsement by the entities themselves.